Advances in glaucoma therapy: Brimonidine tartrate

David S. Greenfield, Jeffrey M. Liebmann, Robert Ritch

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2- imidazoline derivative which is more highly selective for the α2- adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the uveoscleral pathway. Clinical studies have been performed for acute indications using the 0.5% concentration and chronic indications using the 0.2% concentration. This review discusses the mechanism of action, efficacy, and safety of this new compound.

Original languageEnglish (US)
Pages (from-to)127-133
Number of pages7
JournalSeminars in Ophthalmology
Issue number3
StatePublished - Jan 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Advances in glaucoma therapy: Brimonidine tartrate'. Together they form a unique fingerprint.

Cite this